Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small–cell lung cancer (ES-SCLC): a phase II trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small–cell lung cancer (ES-SCLC): a phase II trial

Published:2024-09 Issue: Volume:75 Page:102795
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Chen Dawei,Zou Bing,Li Butuo,Gao Aiqin,Huang Wei,Shao Qian,Meng Xiangjiao,Zhang Pinliang,Tang Xiaoyong,Hu Xudong,Zhang Yan,Guo Jun,Zhao Changhong,Yuan Jiajia,Li Qian,Zhu Changbin,Yu Jinming,Wang Linlin^ORCID

Funder

Jiangsu Hengrui Medicine

National Natural Science Foundation of China

Publisher

Elsevier BV

Reference52 articles.

1. The global burden of lung cancer: current status and future trends;Leiter;Nat Rev Clin Oncol,2023

2. Cancer incidence and mortality in China, 2022;Han;J Natl Cancer Center,2024

3. 1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer;Stahel;Ann Oncol,2011

4. Current standards for clinical management of small cell lung cancer;Farago;Transl Lung Cancer Res,2018

5. Small-cell lung cancer;Rudin;Nat Rev Dis Primers,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP